Open AccessCoenzyme Q 10 Terclatrate and Creatine in Chronic Heart Failure: A Randomized, Placebo‐Controlled, Double‐Blind Study
Author(s) -
Fumagalli Stefano,
Fattirolli Francesco,
Guarducci Lorenzo,
Cellai Tommaso,
Baldasseroni Samuele,
Tarantini Francesca,
Di Bari Mauro,
Masotti Giulio,
Marchionni Niccolò
Publication year - 2011
Publication title -
clinical cardiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.263
H-Index - 72
eISSN - 1932-8737
pISSN - 0160-9289
DOI - 10.1002/clc.20846
Subject(s) - medicine , coenzyme q10 , creatine , heart failure , ejection fraction , placebo , cardiology , creatine kinase , quality of life (healthcare) , randomized controlled trial , vo2 max , placebo controlled study , physical therapy , heart rate , blood pressure , double blind , alternative medicine , nursing , pathology
Background: Studies have suggested that micronutrient deficiency has some role in the progression of chronic heart failure (CHF). Hypothesis: Oral supplementation with coenzyme Q 10 (CoQ 10 ) and creatine may reduce mitochondrial dysfunction that contributes to impaired physical performance in CHF. Methods: We conducted a randomized, double‐blind, placebo‐controlled trial to determine the effect of a mixture of water‐soluble CoQ 10 (CoQ 10 terclatrate; Q‐ter) and creatine on exercise tolerance and health‐related quality of life. Exercise tolerance was measured as total work capacity (kg·m) and peak oxygen consumption (VO 2 , mL/min/kg), both from a cardiopulmonary exercise test. Health‐related quality of life was measured by the Sickness Impact Profile (SIP) in CHF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 35%). After baseline assessment, 67 patients with stable CHF were randomized to receive Q‐ter 320 mg + creatine 340 mg (n = 35) or placebo (n = 32) once daily for 8 weeks. Results: At multivariate analysis, 8‐week peak VO 2 was significantly higher in the active treatment group than in the placebo group (+1.8 ± 0.9 mL/min/kg, 95% CI: 0.1–3.6, P < 0.05). No untoward effects occurred in either group. Conclusions: This study suggests that oral Q‐ter and creatine, added to conventional drug therapy, exert some beneficial effect on physical performance in stable systolic CHF. Results may support the design of larger studies aimed at assessing the long‐term effects of this treatment on functional status and harder outcomes. © 2011 Wiley Periodicals, Inc. The study was supported by an unconditional grant from Scharper Therapeutics, Milan, Italy, which had the responsibility for manufacturing the active treatment and the placebo. The authors have no other funding, financial relationships, or conflicts of interest to disclose.